NIH DIRECTOR WYNGAARDEN LEAVING NIH AUGUST 1
Executive Summary
NIH DIRECTOR WYNGAARDEN LEAVING NIH AUGUST 1; newly appointed HHS Assistant Secretary for Health James Mason will chair a search committee for the new NIH director. Wyngaarden announced his resignation, which was requested by President Bush, at a senior staff meeting on April 20. Wyngaarden became the twelfth director of the agency in 1982. Prior to his appointment as NIH director, Wyngaarden was professor and chairman of the Department of Medicine at Duke University, a post he had held since 1967. Before joining Duke, Wyngaarden spent several years at NIH. From 1953-54, he was a research associate at what was then the National Heart Institute, and from 1954-56, he was a clinical associate at the former National Institute of Arthritis and Metabolic Diseases. Wyngaarden is known as an authority on the regulation of purine biosynthesis and the genetics of gout. He served on several NIH study groups and review panels prior to becoming NIH director; he was also a consultant to the Office of Science and Technology from 1966 to 1972, and a member of the President's Science Advisory Committee from 1972 to 1973. A successor to Wyngaarden has not been named, but National Institute of Allergy and Infectious Diseases Director Anthony Fauci has been rumored for months to be a leading candidate.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth